DRUG NAME: Bleomycin
The drug is cell-cycle specific for G phase, M-phase and S phase. 1. PHARMACOKINETICS: ... Discontinuation of therapy due to these toxicities occurs in about 2% of patients. 6. Febrile reactions. are seen in 50% of patients treated with bleomycin given IV and in …
Download DRUG NAME: Bleomycin
Information
Domain:
Source:
Link to this page:
Documents from same domain
Oncology Nutrition High Protein High Energy …
www.bccancer.bc.caHigh Protein High Energy Food Choices 3 Examples of High Protein Foods • All meat (eg. beef, pork, goat, lamb) • Fish and shellfish • All poultry (eg. chicken, turkey, duck)
BC CANCER HAZARDOUS DRUG LIST
www.bccancer.bc.caBC CANCER HAZARDOUS DRUG LIST (Refer to: Pharmacy Directive VI-80 Hazardous Drug List) The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:
Safe Handling of Hazardous Drugs - BC Cancer
www.bccancer.bc.caA.1 Potential Hazards of Handling Hazardous Drugs..... 1 A.2 Hazardous Drug List.....
“Magic” mouthwash explained - BC Cancer
www.bccancer.bc.caFAMILY PRACTICE ONCOLOGY NETWORK JOURNAL / FALL 2014 3 “Magic” mouthwash explained By Dr. Allan Hovan, Provincial Professional Practice Leader,
Symptom Management Guidelines: ORAL …
www.bccancer.bc.caSymptom Management Guidelines: ORAL MUCOSITIS . Definition Oral Mucositis (Stomatitis): An acute inflammation and/or ulceration of the …
Guidelines for Management of CID - BC Cancer
www.bccancer.bc.caDisclaimer Both the format and content of the guidelines will change as they are reviewed and revised on a periodic basis. Any physician using these guidelines to provide
British Columbia Cancer Agency POLICY
www.bccancer.bc.caBritish Columbia Cancer Agency ¦ POLICY Title: PREVENTION AND MANAGEMENT OF EXTRAVASATION OF CHEMOTHERAPY Number: III-20 Effective Date: Provincial Systemic Program September 1,1997
Symptom Management Guidelines: FEVER AND …
www.bccancer.bc.caSymptom Management Guidelines: FEVER AND NEUTROPENIA . Definition • Fever: A single oral temperature of ≥ 38.3° C (101° F) OR a temperature ≥ 38 ° C (100.4 ° F) which lasts more than 1h
Symptom Management Guidelines: XEROSTOMIA
www.bccancer.bc.caSymptom Management Guidelines: XEROSTOMIA. Definition(s) • Xerostomia: abnormal dryness in the mouth characterized by a marked decrease and/or thickening of saliva, may be
Linking the BC Psychosocial Community Oncology …
www.bccancer.bc.caCarolyn Jacob - New Regional Professional Practice Leader at the Centre for the North. We welcome Carolyn Jacob, MSW, RSW to her new role at the BC
Related documents
DRUG NAME: Capecitabine
www.bccancer.bc.careversal of the effect within weeks of discontinuation of capecitabine, while others exhibit a more persistent effect (e.g., continuing 2 years or more after drug discontinuation). The signific ance of capecitabine-induced adermatoglyphia is the loss of fingerprint identification as well as the loss of the functional quality of the fingertip in
DRUG DEVELOPMENT TARGET PRODUCT PROFILE
drugdevelopment.labcorp.comCovance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world. The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440